3RD SCIENTIFIC SYMPOSIUM OF THE WBMT

16th November 2014
Cape Town - South Africa
Dear friends,

I warmly welcome you to the Third Symposium of the Worldwide Network for Blood and Marrow Transplantation (WBMT) in cooperation with the World Health Organization (WHO) in Cape Town, South Africa. This is a memorable occasion, which represents a big effort of many individuals and societies around the world to continue a series of events aiming at helping countries with restricted resources and transplantation activity. It is certainly unique that many societies active in the field of haematopoietic stem cell transplantation (HSCT) around the world collaborate under the umbrella of the WBMT to offer their decades of experiences to improve and build up programs for a curative treatment for many haematologic and non-haematologic diseases.

In line with the guiding principles of the WHO, we will discuss with delegates of African countries as well as those from North America, South America, Asia Pacific, Europe and Africa, important points on how to optimize or establish a stem cell transplantation program, on current indications for HSCT, donor selection, graft processing, developing an outcome database and the need for a global accreditation system. Since HSCT is a very costly procedure, it is essential to discuss these items under the aspects of restricted resources representing a challenge for presenter and audience.

It is nevertheless also true that HSCT is cost effective from the view of a recipient’s whole life span; therefore, it is a desirable medical technique for emerging countries. Also, the creation and the maintenance of certain infrastructures such as a stem cell banking system, which is essential to offer the opportunity of HSCT to every eligible recipient, will contribute to bring a good atmosphere to each society. Through this workshop, advanced countries will provide information and experiences which have been learned in a “step by step” manner over a relatively long time period.

Emerging countries will be able to hear all recommendations at once and can choose the most appropriate suggestions for themselves. An exchange of ideas in open dialog will also provide a platform whereby both emerging and advanced countries can learn from each other and optimize HSCT outcomes in their own centers. We want this workshop to be a model to offer the opportunity of a “give and take” relationship between emerging countries and advanced countries. We hope all the participants learn together, understand mutually and make this workshop a fruitful one.

The Workshop will also be unique from another standpoint. The guiding principles of the WHO declare regulation of transplantation on a national level as a governmental responsibility. One of the goals of this Workshop is to encourage the integration of HSCT within the healthcare policy of developing countries. This cannot be done without the active participation of politicians, national authorities and representatives of regulatory bodies who responded with enthusiasm and will participate actively during this event.

With this Workshop, the WBMT and its 22 Member Societies are making a further step towards excellence in stem cell transplantation around the world. The 2006 global survey published in JAMA, the first meeting in Hanoi, Vietnam, the second meeting in Salvador, Brazil and the global survey recently published in Haematologica were the initial steps towards this aim. Importantly, the 2011 meeting in Nigeria, during which the African Society for Blood and Marrow Transplantation (AFBMT) was created, led us to this proud moment. Future projects include the creation of a global transplant center number, a donor outcome registry and valuable scientific accomplishments of WBMT Standing Committees, just to mention a few. All these and many more activities are essential for the mission of the WBMT and will require efforts from all of us and the participation of many colleagues and experts around the world.
Let me express my admiration and gratefulness to all people involved in this Workshop starting with Drs. Nicolas Novitzky (AFBMT interim President) and Nosa Bazuyae (AFBMT interim Secretary) and all the people of the AFBMT group. My thanks also go to Dr. Hildegard Greinix and the WBMT Standing Committee Chairs and the Program Planning Committee who in many long telephone conferences were able to create an outstanding program. And Luc Noël and Jose R. Nuñez from the WHO were essential for promoting this event. I also appreciate administrative support provided by Paula Watry.

Without the participation of individuals from many of the WBMT Member Societies, who volunteered their time and expertise, this Workshop would not be possible. I am personally impressed by the enthusiasm and the willingness of many people to pursue this effort and wish you all the best for this Workshop.

Yoshihisa Kodera for the Executive Committee of the WBMT,

a Non-Governmental Organization (NGO) in official relations with the World Health Organization.
Distinguished Delegates and Guests,

It is a great pleasure to welcome you all here to Cape Town, South Africa for the 3rd Global Symposium on Haematopoietic Stem Cells Transplantation in Emerging Countries.

The African Society for Blood and Marrow Transplantation (AFBMT) genuinely thanks the Worldwide Network for Blood & Marrow Transplantation (WBMT) and the World Health Organization (WHO) for mentoring this important and fascinating Workshop. This Workshop aims to provide the opportunity to discuss the clinical, political and administrative needs to promote the development of stem cell transplantation activities in emerging areas and countries with limited resources.

In Salvador, Brazil and earlier in Hanoi, it was shown that these discussions and learning opportunities are possible through the incentive and collaboration of all countries and organizations involved. In addition to the stimulating intellectual and professional discussions and talks promoted by the experts, delegates will have the chance to experience Cape Town, chosen to host this Workshop due to its unique location and past history of HSCT experience.

We trust that the results of this Workshop will be very useful to all participants.

We are greatly honored and privileged to have you all here and wish you a successful Workshop and a pleasant stay in Cape Town.

Nicolas Novitzky, MD  
Interim President/AFBMT

Nosa Bazuaye, MD  
Interim Secretary/AFBMT
Graft engineering: now automated

• T cell depletion using CliniMACS® Reagents
• Reproducibility ensures consistent products
• Save costs with reduced clean-room requirements

Miltenyi Biotec GmbH
Friedrich-Ebert-Straße 68 | 51429 Bergisch Gladbach | Germany
Phone +49 2204 8306-0 | Fax +49 2204 85197 | macs@miltenyibiotec.de
Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are manufactured and controlled under an ISO 13485 certified quality system. In the EU, the CliniMACS System components are available as CE-marked medical devices. In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets T5 and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved. All other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). In the US, the components of the CliniMACS Prodigy System are for research use only and not for human therapeutic or diagnostic use. CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. CliniMACS, CliniMACS Prodigy, and MACS are registered trademarks of Miltenyi Biotec GmbH. Copyright © 2014 Miltenyi Biotec. All rights reserved.

Miltonyi Biotec GmbH
Friedrich-Ebert-Straße 68 | 51429 Bergisch Gladbach | Germany
Phone +49 2204 8306-0 | Fax +49 2204 85197 | macs@miltenyibiotec.de
Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are manufactured and controlled under an ISO 13485 certified quality system. In the EU, the CliniMACS System components are available as CE-marked medical devices. In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets T5 and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved. All other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). In the US, the components of the CliniMACS Prodigy System are for research use only and not for human therapeutic or diagnostic use. CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. CliniMACS, CliniMACS Prodigy, and MACS are registered trademarks of Miltenyi Biotec GmbH. Copyright © 2014 Miltenyi Biotec. All rights reserved.
08:00 - 09:30  OPTIMAL STEM CELL SOURCE & CONDITIONING IN ALLOGENEIC HSCT

Chairs:
Nicolas Novitzky (Cape Town, South Africa)
Dennis Confer (Minneapolis, USA)

08:00  BONE MARROW, PERIPHERAL BLOOD OR CORD BLOOD
Eliane Gluckman (Paris, France)

08:30  HAPLO-IDENTICAL HSCT FROM FAMILY MEMBERS
Dietger Niederwieser (Leipzig, Germany)

08:45  HAPLO-IDENTICAL HSCT: ASIAN EXPERIENCE
Yoshihisa Kodera (Nagoya, Japan)

09:00  MYELOABLATIVE VS REDUCED-INTENSITY CONDITIONING
Daniel Weisdorf (Minneapolis, USA)

09:30 - 09:45  BREAK

09:45 - 11:15  INFECTION COMPLICATIONS OF HSCT

Chairs:
Machteld Oudshoorn, (Leiden, Netherlands)
Mahmoud Aljurf (Riyadh, Saudi Arabia)

09:45  PROPHYLAXIS AND THERAPY OF BACTERIAL AND FUNGAL INFECTIONS
Wieslaw Wiktor-Jedrzejczak (Warsaw, Poland)

10:15  PROPHYLAXIS AND THERAPY OF VIRAL INFECTIONS
Diana Hardie (Cape Town, South Africa)

10:45  MANAGEMENT OF HIV IN THE PERITRANSPLANT PERIOD
Graeme Meintjes (Cape Town, South Africa)

11:15 - 13:15  COMPLICATIONS OF HSCT

Chairs:
Mary Horowitz (Milwaukee, USA)
Nosa Bazuaye (Benin City, Nigeria)

11:15  ORGAN TOXICITIES
Wael Saber (Milwaukee, USA)

11:45  ACUTE GRAFT-VERSUS-HOST DISEASE
Hildegard T. Greinix (Vienna, Austria)

12:15  CHRONIC GRAFT-VERSUS-HOST DISEASE
Joerg Halter (Basel, Switzerland)

12:45  LATE EFFECTS
Naeem Arshad Chaudhri (Riyadh, Saudi Arabia)
SUNDAY - 16TH NOVEMBER 2014

13:15 - 14:15 SATELLITE SYMPOSIUM LUNCH

Satellite Symposium is wholly sponsored by Jazz pharmaceuticals

CRITICAL EARLY COMPLICATIONS OF HSCT: MANAGEMENT & TREATMENT OF VENO-OCCULSIVE DISEASE (VOD)

Chairs:
Yoshihisa Kodera (Nagoya, Japan)
Hildegard Greinix (Vienna, Austria)
Nicolas Novitzky (Cape Town, South Africa)
Mahmoud Aljurf (Riyadh, Saudi Arabia)

13:15 - 13:35 PATHOPHYSIOLOGY & MANAGEMENT OF VOD, INCLUDING A CASE STUDY
Dietger Niederwieser (Leipzig, Germany)

13:35 - 14:05 INTERACTIVE SESSION ON VOD IN AFRICA & EAST MEDITERRANEAN REGION
Mahmoud Aljurf (Riyadh, Saudi Arabia)
Nicolas Novitzky (Cape Town, South Africa)
Nosa Bazuaye (Benin City, Nigeria)

14:05 - 14:15 DISCUSSION

14:15 - 15:45 HSCT IN NON-MALIGNANT DISEASE

Chairs:
Eliane Gluckman (Paris, France)
Alaa El Haddad (Cairo, Egypt)

14:15 HSCT IN HEMOGLOBINOPATHIES
Alok Srivastava (Vellore, India)

14:45 HSCT IN BONE MARROW FAILURES
Menachem Bitan (Tel-Aviv, Israel)

15:15 T-CELL DEPLETION IN HSCT
Nicolas Novitzky (Cape Town, South Africa)

15:45 - 16:00 BREAK

16:00 - 18:00 HSCT IN MALIGNANT DISEASE

Chairs:
Dietger Niederwieser (Leipzig, Germany)
Lamia Torjemane (Tunis, Tunisia)

16:00 ALLOGENEIC HSCT IN LEUKAEMIA AND LYMPHOMA
Wieslaw Wiktor-Jedrzejczak (Warszaw, Poland)

16:30 ALLOGENEIC HSCT FOR PEDIATRIC MALIGNANT DISEASES
Adriana Seber (Sao Paulo, Brazil)

17:00 HSCT IN BURKITT LYMPHOMA
Syed Osman Ahmed (Riyadh, Saudi Arabia)

17:30 HSCT IN MYELOMA
Marcelo Pasquini (Milwaukee, USA)
One Passion.
One Purpose.
One Team.

Committed to creating safe, effective treatments that give hope and health to patients and their loved ones.
GENERAL INFORMATION

DATE
16th November 2014

VENUE
Hotel Southern Sun Cape Town
Strand St
ZA - 8001 Cape Town
South Africa
www.tsogosunhotels.com/hotels/cape-sun

CONGRESS LANGUAGE
English is the official language of the WBMT 2014 Symposium. No simultaneous translation will be provided.

INSURANCE AND LIABILITY
It is recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. WBMT and MCI as organizers cannot accept responsibility for personal injuries, or loss of, or damage to, private property belonging to the congress participants and accompanying persons.

REGISTRATION SEE HOMEPAGE
www.wbmt.org

CONTACT
For any question related to the registration, please contact MCI.
Tel +41 22 33 99 599
Fax +41 22 33 99 631
E-mail: wbmt2014reg@mci-group.com

OFFICE HOURS:
Monday to Friday
9:00 to 18:00
CET - Central European Time
(our offices are open on regular business days with the exception of public holidays)
Today Astellas is working to meet unmet medical needs.

All around the world there are diseases for which no medicine has been developed.

Such unmet medical needs are the battleground of Astellas.

Our mission is to change tomorrow for millions of lives, one drug at a time.

www.astellas.com/en/

Changing tomorrow
TRAVEL GRANT SPONSORS

We are very grateful to our below sponsors for providing travel grants for the symposium.

CHUGAI PHARMACEUTICALS CO. LTD
CLINIGEN HEALTHCARE
GILEAD SCIENCE
JCR PHARMACEUTICALS
MILTenyi BIOTEC GMBH

SPONSORS

AMGEN SOUTH AFRICA
ASTELLAS
ASTELLAS PHARMA (SOUTH AFRICA)
BRISTOL MYERS SQUIBB
CHUGAI PHARMACEUTICAL CO. LTD
CLINIGEN HEALTHCARE
GILEAD SCIENCE
HAEMOTEC
HISTOGENETICS
ISBT
JANSSEN
JAZZ PHARMACEUTICALS
JCR PHARMACEUTICALS CO, LTD

KEY ONCOLOGICS
MILTenyi BIOTEC GMBH
MSD PTY LTD
NIPPONZOKI
NOVARTIS SOUTH AFRICA (PTY) LTD
ONTIME COURIER
OTSUKA PHARMACEUTICAL
ROCHE
TEMA MEDICAL PTY LTD
TERUMO BCT
THERAKOS
THE SCIENTIFIC GROUP
We harness the powers of State Of The Art Technologies for ultimate accuracy and the best resolution